Activity Description & Educational Objectives
In this activity, an expert in the management of diffuse large B-cell lymphoma (DLBCL) discusses the current options for disease management and reviews data on an emerging generation of targeted and other novel agents with promising early activity in this disease.
Upon completion of this activity, participants should be better able to:
- Cite the benefits and limitations of standard management options for diffuse large B-cell lymphoma (DLBCL)
- Summarize safety and efficacy findings on novel targeted therapy across DLBCL management settings
- Demonstrate knowledge of the clinical potential of disease genotyping for more personalized therapy selection
- Describe the current role and/or future potential of radioimmunotherapy in patients with DLBCL
- Recommend clinical trial based therapy for patients with DLBCL who may not benefit from standard options
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncology nurses, and other clinicians involved in the management of large cell lymphoma.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: September 26, 2013 - September 25, 2014
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
John P. Leonard, MD
Professor of Medicine
Weill Cornell Medical College
New York–Presbyterian Hospital
New York, New York
John P. Leonard, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Biotest Pharmaceuticals Corporation; Celgene Corporation; Dr. Reddy's; Genentech, Inc.; Gilead; Hospira, Inc.; MedImmune, LLC.; Onyx; Pharmacyclics; and Teva Pharmaceuticals Industries, Ltd.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5397-14-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.